分组1 - Axogen, Inc. (AXGN) reported a 4Q25 non-GAAP EPS of $0.07, missing expectations by approximately $0.03 [1] - Revenue for the quarter was $59.9 million, aligning with estimates and reflecting a year-over-year growth of 21.3% [1]

Achieved a critical regulatory milestone with FDA approval of the Biologics License Application (BLA) for Avance, establishing it as the first and only approved biologic therapeutic for peripheral nerve discontinuities. Delivered 20.2% full-year revenue growth driven by double-digit expansion across all three target markets: Extremities, Oral Maxillofacial, and Breast. Reached a financial inflection point characterized by positive cash flow and improved profitability, enabling concentrated market deve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ Form 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ ...

Hartley said gross profit was negatively impacted by $1.9 million in one-time costs in the fourth quarter associated with the BLA approval, two-thirds of which were non-cash stock-based compensation tied to milestone vesting. Excluding one-time items, she attributed margin pressure mainly to higher product costs related to additional testing steps as Avance transitioned to a biologic, partially offset by fewer inventory write-offs and lower shipping costs following the case stock program’s discontinuation.G ...

AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50.00%. A quarter ago, it was expected that this regenerative medicine company would post earnings of $0.09 per share when it actually produced earnings of $0.12, delivering a surprise of +33.33%.Over the last four quarter ...

Axogen is a healthcare company specializing in innovative surgical solutions for peripheral nerve injuries, with a diverse product portfolio addressing nerve repair and protection needs. The company leverages proprietary biologic and extracellular matrix technologies to deliver off-the-shelf grafts and coaptation aids, supporting improved clinical outcomes without the need for autograft harvesting. Axogen's strategic focus on expanding its addressable market and serving specialized surgical disciplines unde ...

AxoGen (NasdaqCM:AXGN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsCaitlin Roberts - DirectorJayson Bedford - Managing DirectorJens Schoener - CMOLindsey Hartley - CFOMichael Dale - CEORick Ditto - Medical Device & Life Science ExecutiveSimran Kaur - VPConference Call ParticipantsAnthony Petrone - Managing Director, Senior Medical Devices, Diagnostics and Therapeutics Equity Research AnalystChris Pasquale - Senior AnalystFrank Takkinen - Senior Research AnalystMichael Sarcone - A ...

AxoGen (NasdaqCM:AXGN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsAnthony Petrone - Managing DirectorCaitlin Roberts - DirectorJayson Bedford - Managing DirectorJens Schoener - CMOLindsey Hartley - CFOMichael Dale - CEORick Ditto - Medical Device & Life Science ExecutiveSimran Kaur - VPConference Call ParticipantsChris Pasquale - Senior AnalystFrank Takkinen - Senior Research AnalystMichael Sarcone - AnalystMike Kratky - AnalystOperatorGood morning, everyone. Joining me on today ...

AxoGen (NasdaqCM:AXGN) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker9Good morning, everyone. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and Director, and Lindsey Hartley, Chief Financial Officer. Michael will discuss fourth quarter and full year 2025 financial results and corporate highlights. Lindsey will then provide details on financial performance, guidance, and overall outlook for the year. This will be followed by a question-and-answer session. Today's c ...

Q4 and 2025 Financial Results February 24, 2026 1 Disclaimer Forward-looking Statements This presentation contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995, which are statements that are not historical facts and relate to future conditions, events, or results. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and econom ...